Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tarlatamab for active asymptomatic brain metastases from small cell lung cancer
NL-OMON61047Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC) and brain metastases, sponsored by Maastricht University Medical Center+. Primary endpoint: Intracranial objective response rate. Started Aug 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on NL-OMON61047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61047.